(NASDAQ: ALGS) Aligos Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.9%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.76%.
Aligos Therapeutics's earnings in 2026 is -$66,285,000.On average, 10 Wall Street analysts forecast ALGS's earnings for 2026 to be -$82,583,634, with the lowest ALGS earnings forecast at -$102,630,001, and the highest ALGS earnings forecast at -$56,948,628. On average, 10 Wall Street analysts forecast ALGS's earnings for 2027 to be -$74,028,218, with the lowest ALGS earnings forecast at -$87,933,581, and the highest ALGS earnings forecast at -$47,238,494.
In 2028, ALGS is forecast to generate -$38,984,254 in earnings, with the lowest earnings forecast at -$85,361,708 and the highest earnings forecast at $52,618,433.